Circulating Teff cells are early responders to anti-PD-(L)1 therapy, and changes in circulating Teff cells caused by PD-(L)1 treatment strongly correlate with the prognosis of patients with tumor (31, 49). This evidence concerns the gene CD274 and neoplasm.